DOCSLIB.ORG

IFCC-Worldlab ISTANBUL 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IFCC-Worldlab ISTANBUL 2014 IFCC WORLDLAB ISTANBUL 2014 22nd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC Worldlab 2014) 22nd Balkan Clinical Laboratory Federation Meeting (BCLF 2014) 26th National Congress of the Turkish Biochemical Society (TBS 2014) 22‐26 June 2014 ISTANBUL, TURKEY ISTANBUL CONGRESS CENTER Final Program Using the app, you can display the following : l GENERAL INFORMATION l SCIENTIFIC PROGRAM (with the speakers’ presentations) l POSTERS l SPONSORS l GALLERY Select your device and download the app now at worldlab2014.appconference.it CONTENTS Auspices 4 Contributing Federations/Societies 5 Invitations 6 Committees 8 Executive Boards 10 Turkish Biochemical Society Bursaries 11 IFCC Scholarships 12 SCIENTIFIC PROGRAM Week agenda 14 Opening Ceremony 18 Monday, 23 June 20 Tuesday, 24 June 29 Wednesday, 25 June 39 Thursday, 26 June 47 Closed meetings 54 POSTERS Information 60 Poster list 61 Index of authors 181 GENERAL INFORMATION General maps 232 General information 234 Social program 241 Useful information 243 SPONSORS Information 248 Gold sponsors 249 Silver sponsors 253 Bronze sponsors 255 Exhibitors 262 List of sponsors 284 Exhibition area map 285 The Final Program has been released on June 6th, 2014 3 www.istanbul2014.org AUSPICES IFCC WORLDLAB ISTANBUL 2014 IS ORGANISED UNDER THE PATRONAGE OF THE PRESIDENT OF TURKISH REPUBLIC AND THE AUSPICE OF THE SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TURKEY 4 www.istanbul2014.org CONTRIBUTING FEDERATIONS/SOCIETIES American Association for Clinical Chemistry (AACC) Arab Federation of Clinical Biology (AFCB) African Federation for Clinical Chemistry (AFCC) Asia‐Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB) Balkan Clinical Laboratory Federation (BCLF) Latin America Confederation of Clinical Biochemistry (COLABIOCLI) European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) World Association of Societies of Pathology and Laboratory Medicine (WASPaLM) International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) 5 www.istanbul2014.org INVITATION - Congress President Dear Colleagues, We are very happy to welcome you to IFCC‐WorldLab 2014, in Istanbul, one of the most fascinating cities in the world. Istanbul is not a city only joining Europe and Asia geographically but it is also the meeting point of different cultures. Independent of their original country, I am sure each participant of WorldLab 2014 will feel that their ancesters were here before. IFCC WorldLab 2014 differs from the preceding IFCC Congresses because for the first time, in the history of IFCC, all the sister societies are together; AACC (American Association of Clinical Chemistry), AFCB (Arab Federation of Clinical Biology), AFCC (African Federation of Clinical Chemistry), APFCB (Asia‐Pasific Federation for Clinical Biochemistry and Laboratory Medicine), BCLF (Balkan Clinical Laboratory Federation), COLABIOCLI (Latin America Confederation of Clinical Biochemistry), EFLM (European Federation of Clinical Chemistry and Laboratory Medicine) and WASPaLM (World Association of Societies of Pathology and Laboratory Medicine) and they are contributing to IFCC WorldLab/Istanbul Congress with a symposium. We are happy to state that many colleagues from all over the world had joined us. We are sure that this congress will be one of the unforgettable IFCC WorldLab Congresses. Istanbul will host a large delegation of the international medical laboratory scientists for the main happening of the year and we are ready for this big event. Many of you have done your best by submitting an abstract to the IFCC WorldLab 2014 Istanbul Congress. We are grateful that we received more than 1600 abstracts, which is a record for the IFCC WorldLab Congresses. All participants are encouraged to visit the poster area and use the opportunity to obtain new ideas. The Scientific Program includes: One outstanding Opening Lecture; 4 Plenary Lectures, from the world’s most renowned scientists; 26 Congress Symposia covering the most attractive topics; 42 Oral Communications selected from the abstracts; 1552 posters displayed; 8 Symposia organized by contributing sister Federations/Societies; 5 IFCC Sessions; 23 Industry‐Sponsored Workshops; 3 Satellite meetings (XIII. ICPLM, PoCT, LC‐MS/MS in Clinical Chemistry); An education workshop by the IFCC – FEBS – ORPHEUS education committees on “PhD training in Clinical Chemistry, Clinical Biochemistry, and Laboratory Medicine: Where are we heading?”; 3 poster lunch sessions. There will be enough science for everyone during the day. During the evenings, a rich social program providing the frame for relaxation and cultural stimulation has been developed for attendees, families and friends. Opening ceremony with an “Opening Lecture” followed by Cihat Aşkın orchestra and solist clarinet Göksun Çavdar will be and the welcome cocktail. A course on EBRU, unique art for Turkish culture, is organised on the 23rd and 24th of June, 2014, between 13:00 – 17:00 hours. Particularly, we would like to draw your attention to the Cultural and Social Evening on Wednesday (25th June, 2014) at the historic mansion “The Marmara Esma Sultan Palace” so, please do not hesitate to register for this major social event of the WorldLab2014 Istanbul Congress. On behalf of the Organising Committee, it gives us great pleasure to welcome you in Istanbul, and we wish you a fruitful, interactive and enjoyable Congress. Enjoy, also, the beauties of Istanbul and Turkey! Warm Regards, Professor Nazmi ÖZER, PhD, MedSp President, IFCC WorldLab Congress 6 www.istanbul2014.org INVITATION - IFCC President Dear Colleagues, I have great pleasure in welcoming you to IFCC‐WorldLab Istanbul 2014. Istanbul is one of the most exciting cities in the world standing at the gateway between Europe and Asia. It has both an historical and a contemporary influence on science, culture, politics and society. There is much to see and do in the city itself and much to learn from the dynamic and positive approach to the future. IFCC‐WorldLab occurs only once in every three years. As the name suggests it is the global, showpiece international congress for clinical chemistry and laboratory medicine. The scientific program contains high quality science coupled with a strong focus on how important laboratory medicine services are to clinical medicine and the wellbeing of patients and the public. The way in which we deliver and add value to those services is also a highlight of the programme. There is ample opportunity for individual participants to present and discuss their work with their peers. Our profession is in a growing partnership with the clinical diagnostic industry. The exhibition of equipment, diagnostics, software and the industrial seminars are at the sharp end of discovery and delivery and will encourage participants to consider new and exciting ways to improve the laboratory medicine services that they provide. However, above all else congresses are about people. At IFCC‐WorldLab Istanbul 2014 participants will see established colleagues and meet new friends from across the globe. They will find individuals who share scientific and clinical interests and they will have the opportunity to establish long lasting research and clinical practice networks. We can all learn from the experience of others and there is no better place to do this than at a dynamic congress. I am confident that IFCC‐WorldLab Istanbul 2014 will be a highly successful congress with a strong emphasis on a positive future. It will also be hugely enjoyable. Your presence will add to that success and that enjoyment. Graham H Beastall IFCC President International Federation of Clinical Chemistry and Laboratory Medicine 7 www.istanbul2014.org COMMITTEES HONORARY COMMITTEE V. Blaton (Belgium) R. Dybkaer (Denmark) J.M.B. Hicks (USA) M.M. Müller (Austria) S. Ozkurt (Turkey) M. McQueen (Canada) G. Siest (France) D. Young (USA) CONGRESS ORGANIZING COMMITTEE N. Ozer (Turkey), Congress President D. Yucel (Turkey), Vice‐President T. Ozben (Turkey), Chair IFCC C‐CC T. Zima (Czech Republic), IFCC C‐CC T. Brinkmann (Switzerland), IFCC Corporate Member Z. G. Dikmen (Turkey), Secretary M. Senes (Turkey), Finance O. Dalmizrak (Turkey), Scientific Secretary A. Seven (Turkey), Chair Istanbul Branch of Turkish Biochemical Society INTERNATIONAL SCIENTIFIC COMMITTEE N. Ozer (Turkey), Congress President Y. Ozarda (Turkey) D. Yucel (Turkey), Vice ‐ President M. Panteghini (Italy) K. Aksoy (Turkey) O. Portakal (Turkey) D. Aslan (Turkey) H. Renz (Germany) G. Beastall (United Kingdom) F.G. Sagin (Turkey) G. Benga (Romania) M. Serdar (Turkey) M. Bolayirli (Turkey) E.Y. Sozmen (Turkey) M.B. Djamgoz (United Kingdom) K. Ugurbil (USA) A.R. Horvath (Australia) A. Unlu (Turkey) G. Hotamisligil (USA) I. Watson (United Kingdom) G. Mocan Kuzey (Turkey) I. Young (United Kingdom) Y. Laleli (Turkey) LOCAL SCIENTIFIC PROGRAM COMMITTEE D. Yucel (Turkey), Committee Chair A. Orem (Turkey) D. Aslan (Turkey) M. Serdar (Turkey) O. Guzel (Turkey) E.Y. Sozmen (Turkey) G. Haklar (Turkey) A. Unlu (Turkey) Y. Laleli (Turkey) 8 www.istanbul2014.org COMMITTEES INTERNATIONAL SCIENTIFIC ADVISORY BOARD N. Ozer (Turkey), Congress P. Gillery (France) P. Pidethcha (Thailand) President A. Griesmacher (Austria) M. Plebani (Italy) D. Yucel (Turkey), Vice – A. M. Gronowski (USA) K. Pulkki (Finland) President B. Gouget (France) Mj Rasaee (Iran) J. C. Guimaraes (Brazil) S. Raymondo (Uruguay) Z. M. Abate (Ethiopia) M. Gultepe (Turkey) H. Reguengo (Portugal)
Load more

Recommended publications
  • Genetics of Interleukin 1 Receptor-Like 1 in Immune and Inflammatory Diseases
    Current Genomics, 2010, 11, 591-606 591 Genetics of Interleukin 1 Receptor-Like 1 in Immune and Inflammatory Diseases Loubna Akhabir and Andrew Sandford* Department of Medicine, University of British Columbia, UBC James Hogg Research Centre, Providence Heart + Lung Institute, Room 166, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada Abstract: Interleukin 1 receptor-like 1 (IL1RL1) is gaining in recognition due to its involvement in immune/inflamma- tory disorders. Well-designed animal studies have shown its critical role in experimental allergic inflammation and human in vitro studies have consistently demonstrated its up-regulation in several conditions such as asthma and rheumatoid ar- thritis. The ligand for IL1RL1 is IL33 which emerged as playing an important role in initiating eosinophilic inflammation and activating other immune cells resulting in an allergic phenotype. An IL1RL1 single nucleotide polymorphism (SNP) was among the most significant results of a genome-wide scan inves- tigating eosinophil counts; in the same study, this SNP associated with asthma in 10 populations. The IL1RL1 gene resides in a region of high linkage disequilibrium containing interleukin 1 receptor genes as well as in- terleukin 18 receptor and accessory genes. This poses a challenge to researchers interested in deciphering genetic associa- tion signals in the region as all of the genes represent interesting candidates for asthma and allergic disease. The IL1RL1 gene and its resulting soluble and receptor proteins have emerged as key regulators of the inflammatory proc- ess implicated in a large variety of human pathologies We review the function and expression of the IL1RL1 gene.
    [Show full text]
  • Interleukin-18 As a Therapeutic Target in Acute Myocardial Infarction and Heart Failure
    Interleukin-18 as a Therapeutic Target in Acute Myocardial Infarction and Heart Failure Laura C O’Brien,1 Eleonora Mezzaroma,2,3,4 Benjamin W Van Tassell,2,3,4 Carlo Marchetti,2,3 Salvatore Carbone,2,3 Antonio Abbate,1,2,3 and Stefano Toldo2,3 1Department of Physiology and Biophysics, 2Victoria Johnson Research Laboratories, and 3Virginia Commonwealth University Pauley Heart Center, School of Medicine, and 4Pharmacotherapy and Outcome Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States of America Interleukin 18 (IL-18) is a proinflammatory cytokine in the IL-1 family that has been implicated in a number of disease states. In animal models of acute myocardial infarction (AMI), pressure overload, and LPS-induced dysfunction, IL-18 regulates cardiomy- ocyte hypertrophy and induces cardiac contractile dysfunction and extracellular matrix remodeling. In patients, high IL-18 levels correlate with increased risk of developing cardiovascular disease (CVD) and with a worse prognosis in patients with established CVD. Two strategies have been used to counter the effects of IL-18:IL-18 binding protein (IL-18BP), a naturally occurring protein, and a neutralizing IL-18 antibody. Recombinant human IL-18BP (r-hIL-18BP) has been investigated in animal studies and in phase I/II clinical trials for psoriasis and rheumatoid arthritis. A phase II clinical trial using a humanized monoclonal IL-18 antibody for type 2 diabetes is ongoing. Here we review the literature regarding the role of IL-18 in AMI and heart failure and the evidence and challenges of using IL-18BP and blocking IL-18 antibodies as a therapeutic strategy in patients with heart disease.
    [Show full text]
  • Biomarker Quantitation Assay Guide
    Biomarker quantitation assay guide Quantitate protein: ELISA l Antibody pairs l ProQuantum HS immunoassays l ProcartaPlex immunoassays Quantitate mRNA: QuantiGene multiplexed gene expression assays Our Invitrogen™ portfolio offers a variety of assays for quantitation of single proteins and mRNA, as well as mix-and-match and ready-to-use panels for correlated multiplexing using the Luminex® platform. Our extensive portfolio of assays includes: • ELISA and antibody pair kits • ProQuantum™ high-sensitivity immunoassay kits • ProcartaPlex™ multiplex immunoassay kits • QuantiGene™ Plex gene expression assays Additionally, Thermo Fisher Scientific supports your quantitation assay needs with accessory reagents and instruments for a comprehensive offering. Use this guide to help identify your needs, and then contact your sales representative if you have questions or go to thermofisher.com/quantitatebiomarkers Contents Biomarker background 4 Biomarker quantitation assay platforms 7 Single-analyte quantitation ELISA kits 9 Antibody pair kits 11 ProQuantum high-sensitivity immunoassay kits 12 Accessory reagents and equipment 14 Multianalyte quantitation Luminex xMAP technology 17 ProcartaPlex multiplex immunoassay kits 19 ProcartaPlex high-sensitivity immunoassay kits 27 ProcartaPlex Platinum immunoassay kits 28 Custom assay development service 30 Multiplexed gene expression assays 32 QuantiGene Plex assays 32 Additional gene expression solutions 38 Comprehensive immunoassay product listing 40 Biomarker background Highly referenced kits you can
    [Show full text]
  • The Relevance of Clinical, Genetic and Serological Markers
    AUTREV-01901; No of Pages 18 Autoimmunity Reviews xxx (2016) xxx–xxx Contents lists available at ScienceDirect Autoimmunity Reviews journal homepage: www.elsevier.com/locate/autrev Review Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers Raquel López-Mejías a, Santos Castañeda b, Carlos González-Juanatey c,AlfonsoCorralesa, Iván Ferraz-Amaro d, Fernanda Genre a, Sara Remuzgo-Martínez a, Luis Rodriguez-Rodriguez e, Ricardo Blanco a,JavierLlorcaf, Javier Martín g, Miguel A. González-Gay a,h,i,⁎ a Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain b Division of Rheumatology, Hospital Universitario la Princesa, IIS-IPrincesa, Madrid, Spain c Division of Cardiology, Hospital Lucus Augusti, Lugo, Spain d Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain e Division of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain f Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain g Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain h School of Medicine, University of Cantabria, Santander, Spain i Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa article info abstract Article history: Cardiovascular disease (CV) is the most common cause of premature mortality in patients with rheumatoid ar- Received 7 July 2016 thritis (RA). This is the result of an accelerated atherosclerotic process. Adequate CV risk stratification has special Accepted 9 July 2016 relevance in RA to identify patients at risk of CV disease.
    [Show full text]
  • Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure: the HOMAGE Study
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Enlighten Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi:10.1161/CIRCHEARTFAILURE.118.005897) This is the author’s final accepted version. There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it. http://eprints.gla.ac.uk/186516/ Deposited on: 13 May 2019 Enlighten – Research publications by members of the University of Glasgow http://eprints.gla.ac.uk Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure: the HOMAGE (Heart OMics in AGEing) study João Pedro Ferreira, MD, PhD1,2* & Job Verdonschot, MD3,4*; Timothy Collier, PhD5; Ping Wang, PhD4; Anne Pizard, PhD1,6; Christian Bär, MD, PhD7; Jens Björkman, PhD8; Alessandro Boccanelli, MD9; Javed Butler, MD, PhD10; Andrew Clark, MD, PhD11; John G. Cleland, MD, PhD12,13; Christian Delles, MD, PhD14; Javier Diez, MD, PhD15,16,17,18; Nicolas Girerd, MD, PhD1; Arantxa González, MD, PhD15,16,17; Mark Hazebroek, MD, PhD3; Anne-Cécile Huby, PhD1; Wouter Jukema, MD, PhD19; Roberto Latini, MD, PhD20; Joost Leenders, MD, PhD21; Daniel Levy, MD, PhD22,23; Alexandre Mebazaa, MD, PhD24; Harald Mischak, MD, PhD25; Florence Pinet, MD, PhD26; Patrick Rossignol, MD, PhD1; Naveed Sattar, MD, PhD27; Peter Sever, MD, PhD28; Jan A. Staessen, MD, PhD29,30; Thomas Thum, MD, PhD7,31; Nicolas Vodovar, PhD24; Zhen-Yu Zhang, MD29; Stephane Heymans, MD, PhD3,32,33** & Faiez Zannad, MD, PhD1** *co-first authors **co-last authors 1 Université de Lorraine, Inserm, Centre d’Investigations Cliniques- Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
    [Show full text]
  • Interleukin-18 in Health and Disease
    International Journal of Molecular Sciences Review Interleukin-18 in Health and Disease Koubun Yasuda 1 , Kenji Nakanishi 1,* and Hiroko Tsutsui 2 1 Department of Immunology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; [email protected] 2 Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-798-45-6573 Received: 21 December 2018; Accepted: 29 January 2019; Published: 2 February 2019 Abstract: Interleukin (IL)-18 was originally discovered as a factor that enhanced IFN-γ production from anti-CD3-stimulated Th1 cells, especially in the presence of IL-12. Upon stimulation with Ag plus IL-12, naïve T cells develop into IL-18 receptor (IL-18R) expressing Th1 cells, which increase IFN-γ production in response to IL-18 stimulation. Therefore, IL-12 is a commitment factor that induces the development of Th1 cells. In contrast, IL-18 is a proinflammatory cytokine that facilitates type 1 responses. However, IL-18 without IL-12 but with IL-2, stimulates NK cells, CD4+ NKT cells, and established Th1 cells, to produce IL-3, IL-9, and IL-13. Furthermore, together with IL-3, IL-18 stimulates mast cells and basophils to produce IL-4, IL-13, and chemical mediators such as histamine. Therefore, IL-18 is a cytokine that stimulates various cell types and has pleiotropic functions. IL-18 is a member of the IL-1 family of cytokines. IL-18 demonstrates a unique function by binding to a specific receptor expressed on various types of cells.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Human ST2/IL-33 R ELISA Kit
    Human ST2/IL-33 R ELISA Kit Catalog #: AYQ-E11208 (96 wells) User Manual This kit is designed to quantitatively detect the levels of Human ST2/IL-33 R in cell lysates, serum/ plasma and other suitable sample solution. Manufactured and Distributed by: AssaySolution 310 W Cummings Park, Woburn, MA, 01801, USA Phone: (617) 238-1396, Fax: (617) 380-0053 Email: [email protected] FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PURPOSES Important notes Before using this product, please read this manual carefully; after reading the subsequent contents of this manual, please note the following specially: • The operation should be carried out in strict accordance with the provided instructions. • Store the unused strips in a sealed foil bag at 2-8°C. • Always avoid foaming when mixing or reconstituting protein solutions. • Pipette reagents and samples into the center of each well, avoid bubbles. • The samples should be transferred into the assay wells within 15 minutes of dilution. • We recommend that all standards, testing samples are tested in duplicate. • Using serial diluted sample is recommended for first test to get the best dilution factor. • If the blue color develops too light after 15 minutes incubation with the substrate, it may be appropriate to extend the incubation time (Do not over-develop). • Avoid cross-contamination by changing tips, using separate reservoirs for each reagent. • Avoid using the suction head without extensive wash. • Do not mix the reagents from different batches. • Stop Solution should be added in the same order of the Substrate Solution. • TMB developing agent is light-sensitive. Avoid prolonged exposure to the light.
    [Show full text]
  • Analyte Quarterly V2
    NEW PANELS SPOTLIGHT Bring Your Biomarkers to Life HUMAN Your comprehensive guide to multiplex and single protein detection. Analyte Quarterly, Vol. 2 2017 MOUSE RAT • MILLIPLEX® map Assays • SMC™ (Single Molecule Counting) Assays CELL SIGNALING • ELISA • RIA • GyroMark™ HT Assays • Custom Assay Development INSTRUMENTS SINGLE PROTEIN CUSTOM The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Platforms Fit for Your Purpose We're here to guide you to choose the best protein detection platform for your needs Flexibility and sensitivity: our platforms fit your purpose Protein Custom PROTEIN DETECTION PLATFORMS PROTEIN Detection Sample Dynamic Multiplex Assay Platforms Fit for Purpose Quantitative Sensitivity Volume Range Capability Support Luminex® platform Multiplex detection Yes pg/mL ≤ 25 µL ••• Yes Flexible platform SMCxPRO™ or Erenna® system Ultrasensitivity Yes fg/mL 5–100 µL ••• Yes High performance ELISA Plate reader compatibility Yes pg/mL 50–100 µL •• Yes Most widely cited Gyrolab® workstation Fully automated Yes pg/mL < 5 µL ••• Yes High precision • Good Performance •• Strong Performance ••• Superior Performance Not Recommended Recommended MILLIPLEX® map multiplex detection: rely on the quality we build into each panel to produce results you trust In addition to the assay specifications listed in the protocol, we evaluate other performance criteria during our validation process: cross-reactivity, dilution linearity, kit stability, and sample behavior (e.g., detectability and stability). MILLIPLEX® map assays offer the broadest selection of analytes across a wide range of research areas and species. SMC™ assays for use with SMCxPRO™ or Erenna® instruments: Previously undetectable, now quantified, one molecule at a time Combine a traditional immunoassay workflow with ultrasensitive Single Molecule Counting (SMC™) technology (developed by Singulex®, Inc.) to quantify concentrations down to the femtogram/mL level.
    [Show full text]
  • A Review on Application of Biomarkers in Heart Failure
    Indian Journal of Biochemistry & Biophysics Vol. 55, October 2018, pp. 303-313 A Review A review on application of biomarkers in heart failure Bobbala Indumathi, Shiva Krishna Katkam & Vijay Kumar Kutala* Department of Clinical Pharmacology & Therapeutics, Nizam’s Institute of Medical Sciences, Hyderabad-500 082, India Received 03 May 2018; revised 22 May 2018 Heart failure (HF) remains the leading cause of death in the elderly population. Since last decade there is an advance in the field of biomarkers in managing these patients. Hence identifying novel and potential biomarkers that help in accessing the risk, predicting the disease and monitoring the prognosis is very crucial in reducing the overall morbidity and mortality. These biomarkers are elevated mainly in response to myocardial stress, dynamic changes in extracellular matrix, myocyte necrosis, oxidative stress, and inflammation. The biomarker that has good clinical correlations may be useful in diagnosis, prognosis, and therapeutic management of HF. Understanding the role of each biomarker and their clinical implication is very crucial. In this review, we summarize the attainments and challenges of using different types of biomarkers in HF. Keywords: Atrial natriuretic peptide, B-type natriuretic peptide, Galectin-3, Heart failure, High sensitivity troponin, Natriuretic peptides, Neutrophil gelatinase-associated lipocalin, Peptides, ST2 Heart failure (HF) is generally a chronic condition and is heart to pump blood at proportionate rate to the major public health problem in developed countries metabolizing tissues during regular activity9. The like the USA with a prevalence of over 5.8 million, and various factors such as ischemic heart disease (IHD), over 23 million worldwide1,2.
    [Show full text]
  • IL-1 Family Cytokines in Cardiovascular Disease
    Cytokine 122 (2019) 154215 Contents lists available at ScienceDirect Cytokine journal homepage: www.elsevier.com/locate/cytokine IL-1 family cytokines in cardiovascular disease T ⁎ Susanne Pfeilera, Holger Winkelsb, Malte Kelma, Norbert Gerdesa,c, a Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany b Division of Inflammation Biology, La Jolla Institute for Allergy & Immunology, La Jolla, CA, United States c Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany ARTICLE INFO ABSTRACT Keywords: The interleukin (IL)-1 family is a group of cytokines crucially involved in regulating immune responses to in- Interleukin fectious challenges and sterile insults. The family consists of the eponymous pair IL-1α and IL-1β, IL-18, IL-33, IL-1 IL-37, IL-38, and several isoforms of IL-36. In addition, two endogenous inhibitors of functional receptor binding, IL-18 IL-1R antagonist (IL-1Ra) and IL-36Ra complete the family. To gain biological activity IL-1β and IL-18 require Caspase 1 processing by the protease caspase-1 which is associated with the multi-protein complex inflammasome. Inflammasome Numerous clinical association studies and experimental approaches have implicated members of the IL-1 family, Cardiovascular disease their receptors, or component of the processing machinery in underlying processes of cardiovascular diseases (CVDs). Here we summarize the current state of knowledge regarding the pro-inflammatory and disease-mod- ulating role of the IL-1 family in atherosclerosis, myocardial infarction, aneurysm, stroke, and other CVDs. We discuss clinical evidence, experimental approaches and lastly lend a perspective on currently developing ther- apeutic strategies involving the IL-1 family in CVD.
    [Show full text]
  • Abstracts BOOK
    CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE TRANSLATING SCIENCE INTO SURVIVAL SEPTEMBER 25th to 28th, 2019 - PARIS Abstracts BOOK www.cancerimmunotherapyconference.org SESSION A fined as complete response or partial response or stable disease POSTER SESSION A for at least 8 weeks) of 45% (17/38). ORR was 11% (2/19) in PD-L1 negative and 17% (2/12) in PD-L1 positive pts. Pts with 2 lines or more of prior therapy had an ORR of 20% (5/25), regardless of PD-L1 status. Treatment-related Grade 3/4 AEs occurred in 23% Combination therapies with immune of pts, with dehydration, hypotension, and myalgia as the most checkpoint blockers frequently reported (4.7% each), consistent with previous reports. Conclusion : Clinical activity was observed in mTNBC pts treated A001 / Clinical activity of BEMPEG plus NIVO observed in with BEMPEG plus NIVO, notably in pts with poor prognostic fea- tures or negative predictive clinical factors for CPI benefit, includ- metastatic TNBC : preliminary results from the TNBC co- ing negative PD-L1 status. Additional efficacy analyses, including hort of the Ph1/2 PIVOT-02 study ORR, duration of response, and biomarker analyses, will be pre- sented. These data support future development of this doublet in mTNBC pts who are PD-L1 negative at baseline, in combination Sara Tolaney (Dana-Farber Cancer Institute), Capucine Baldini with chemotherapy. This study (NCT02983045) and registration- (Institut Gustave Roussy), Alexander Spira (Virginia Cancer Spe- al studies in other solid tumor settings are ongoing. cialists), Daniel Cho (New York University Langone Medical Cen- ter - NYU Cancer Institute), Giovanni Grignani (Fondazione del Piemonte per l Oncologia IRCCS Candiolo), Dariusz Sawka (POO Keywords : BEMPEG, NKTR-214, Triple-negative breast cancer, Szpital Specjalistyczny w Brzozowie), Fabricio Racca (Instituto Nivolumab.
    [Show full text]